Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.

Inagaki N, Yang W, Watada H, Ji L, Schnaidt S, Pfarr E, Okamura T, Johansen OE, George JT, von Eynatten M, Rosenstock J, Perkovic V, Wanner C, Cooper ME, Alexander JH, Komuro I, Nangaku M.

Diabetol Int. 2019 Oct 22;11(2):129-141. doi: 10.1007/s13340-019-00412-x. eCollection 2020 Apr.

PMID:
32206483
2.

Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

Neuen BL, Jardine MJ, Perkovic V.

Nephrol Dial Transplant. 2020 Jan 1;35(Supplement_1):i48-i55. doi: 10.1093/ndt/gfz252.

3.

Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B.

J Am Heart Assoc. 2020 Feb 4;9(3):e014908. doi: 10.1161/JAHA.119.014908. Epub 2020 Jan 29.

4.

Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials.

Neuen BL, Perkovic V.

J Am Soc Nephrol. 2020 Jan;31(1):4-6. doi: 10.1681/ASN.2019111196. Epub 2019 Dec 17. No abstract available.

PMID:
31871251
5.

Inequities in the global representation of sites participating in large, multicentre dialysis trials: a systematic review.

Smyth B, Trongtrakul K, Haber A, Talbot B, Hawley C, Perkovic V, Woodward M, Jardine M.

BMJ Glob Health. 2019 Nov 12;4(6):e001940. doi: 10.1136/bmjgh-2019-001940. eCollection 2019.

6.

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.

Ohkuma T, Van Gaal L, Shaw W, Mahaffey KW, de Zeeuw D, Matthews DR, Perkovic V, Neal B.

Diabetes Obes Metab. 2020 Apr;22(4):530-539. doi: 10.1111/dom.13920. Epub 2020 Jan 3.

7.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.

Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW.

Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11. No abstract available.

PMID:
31707795
8.

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.

Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, Neal B.

JACC Heart Fail. 2020 Jan;8(1):57-66. doi: 10.1016/j.jchf.2019.08.004. Epub 2019 Oct 29.

9.

Varying Association of Extended Hours Dialysis with Quality of Life.

Smyth B, van den Broek-Best O, Hong D, Howard K, Rogers K, Zuo L, Gray NA, de Zoysa JR, Chan CT, Lin H, Zhang L, Xu J, Cass A, Gallagher M, Perkovic V, Jardine M.

Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1751-1762. doi: 10.2215/CJN.06800619. Epub 2019 Oct 31.

PMID:
31672793
10.

Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey.

Bello AK, Levin A, Lunney M, Osman MA, Ye F, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Davison SN, Ghnaimat M, Harden P, Htay H, Jha V, Kalantar-Zadeh K, Kerr PG, Klarenbach S, Kovesdy CP, Luyckx VA, Neuen BL, O'Donoghue D, Ossareh S, Perl J, Rashid HU, Rondeau E, See E, Saad S, Sola L, Tchokhonelidze I, Tesar V, Tungsanga K, Turan Kazancioglu R, Wang AY, Wiebe N, Yang CW, Zemchenkov A, Zhao MH, Jager KJ, Caskey F, Perkovic V, Jindal KK, Okpechi IG, Tonelli M, Feehally J, Harris DC, Johnson DW.

BMJ. 2019 Oct 31;367:l5873. doi: 10.1136/bmj.l5873.

11.

Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

Neuen BL, Cherney DZ, Jardine MJ, Perkovic V.

CMAJ. 2019 Oct 15;191(41):E1128-E1135. doi: 10.1503/cmaj.190047. Review. No abstract available.

12.

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Li Q, Jardine M, Oh R, Heerspink HL, Perkovic V.

J Am Soc Nephrol. 2019 Nov;30(11):2229-2242. doi: 10.1681/ASN.2019010064. Epub 2019 Sep 17.

13.

Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply.

Jardine MJ, Mahaffey KW, Perkovic V.

N Engl J Med. 2019 Sep 12;381(11):1089-1090. doi: 10.1056/NEJMc1909687. No abstract available.

PMID:
31509685
14.

Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial.

Perkovic V, Koitka-Weber A, Cooper ME, Schernthaner G, Pfarr E, Woerle HJ, von Eynatten M, Wanner C.

Nephrol Dial Transplant. 2019 Sep 8. pii: gfz179. doi: 10.1093/ndt/gfz179. [Epub ahead of print]

PMID:
31495881
15.

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ.

Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5. Erratum in: Lancet Diabetes Endocrinol. 2019 Dec;7(12):e23.

PMID:
31495651
16.

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.

Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K.

Am J Kidney Dis. 2020 Jan;75(1):84-104. doi: 10.1053/j.ajkd.2019.06.009. Epub 2019 Aug 28.

PMID:
31473020
17.

Blood pressure: at what level is treatment worthwhile?

Atkins ER, Perkovic V.

Aust Prescr. 2019 Aug;42(4):127-130. doi: 10.18773/austprescr.2019.038. Epub 2019 Aug 1. Review. No abstract available. Erratum in: Aust Prescr. 2019 Oct;42(5):175. Erratum in: Aust Prescr. 2020 Feb;43(1):33.

18.

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.

Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B.

Diabetologia. 2019 Oct;62(10):1854-1867. doi: 10.1007/s00125-019-4955-5. Epub 2019 Aug 10.

19.

Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis.

Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, Jardine MJ, Sood MM, Garg AX, Palmer SC, Mark PB, Wheeler DC, Jha V, Freedman B, Johnson DW, Perkovic V, Badve SV.

Ann Intern Med. 2019 Aug 6;171(3):181-189. doi: 10.7326/M19-0087. Epub 2019 Jul 16.

PMID:
31307056
20.

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study.

Oshima M, Jun M, Ohkuma T, Toyama T, Wada T, Cooper ME, Hadjadj S, Hamet P, Harrap S, Mancia G, Marre M, Williams B, Chalmers J, Woodward M, Perkovic V; ADVANCE Collaborative Group.

Diabetologia. 2019 Nov;62(11):1988-1997. doi: 10.1007/s00125-019-4948-4. Epub 2019 Jul 13.

21.

Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study.

Zhan Z, Smyth B, Toussaint ND, Gray NA, Zuo L, de Zoysa JR, Chan CT, Jin C, Scaria A, Hawley CM, Perkovic V, Jardine MJ, Zhang L.

BMC Nephrol. 2019 Jul 12;20(1):258. doi: 10.1186/s12882-019-1438-3.

22.

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T.

J Am Soc Nephrol. 2019 Sep;30(9):1735-1745. doi: 10.1681/ASN.2019010007. Epub 2019 Jul 10.

PMID:
31292197
23.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V.

Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11.

24.

Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis.

Smyth B, Haber A, Trongtrakul K, Hawley C, Perkovic V, Woodward M, Jardine M.

JAMA Intern Med. 2019 Jul 8. doi: 10.1001/jamainternmed.2019.1501. [Epub ahead of print] Erratum in: JAMA Intern Med. 2019 Oct 1;179(10):1448.

PMID:
31282924
25.

Is it time to REWIND the cardiorenal clock in diabetes?

Verma S, Mazer CD, Perkovic V.

Lancet. 2019 Jul 13;394(10193):95-97. doi: 10.1016/S0140-6736(19)31267-X. Epub 2019 Jun 9. No abstract available.

PMID:
31189510
26.

Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes.

Ohkuma T, Jun M, Chalmers J, Cooper ME, Hamet P, Harrap S, Zoungas S, Perkovic V, Woodward M; ADVANCE Collaborative Group.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):862-872. doi: 10.2215/CJN.13391118. Epub 2019 Jun 3.

PMID:
31160317
27.

Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Cheung AK, Chang TI, Cushman WC, Furth SL, Ix JH, Pecoits-Filho R, Perkovic V, Sarnak MJ, Tobe SW, Tomson CRV, Cheung M, Wheeler DC, Winkelmayer WC, Mann JFE; Conference Participants.

Kidney Int. 2019 May;95(5):1027-1036. doi: 10.1016/j.kint.2018.12.025.

28.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
29.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

30.

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.

Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.

Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.

31.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.

Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Hiatt WR, Nehler M, Fabbrini E, Kavalam M, Lee M, Neal B.

Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.

32.

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.

Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, Rogers K, Gallagher M.

PLoS One. 2019 Mar 7;14(3):e0213192. doi: 10.1371/journal.pone.0213192. eCollection 2019.

33.

Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial.

Garg AX, Chan MTV, Cuerden MS, Devereaux PJ, Abbasi SH, Hildebrand A, Lamontagne F, Lamy A, Noiseux N, Parikh CR, Perkovic V, Quantz M, Rochon A, Royse A, Sessler DI, Shah PJ, Sontrop JM, Tagarakis GI, Teoh KH, Vincent J, Walsh M, Yared JP, Yusuf S, Whitlock RP; SIRS Investigators.

CMAJ. 2019 Mar 4;191(9):E247-E256. doi: 10.1503/cmaj.181644.

34.

Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol.

Smyth B, Krishnan AV, Gallagher M, Kiernan M, Snelling P, Hawley C, Fernando M, Hand S, Grimley K, Burman J, Heath A, Kang A, Perkovic V, Jardine MJ.

BMJ Open. 2019 Jan 15;9(1):e023736. doi: 10.1136/bmjopen-2018-023736.

35.

Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial.

Gray NA, Zuo L, Hong D, Smyth B, Jun M, De Zoysa J, Vo K, Howard K, Wang J, Lu C, Liu Z, Cass A, Perkovic V, Jardine M.

Nephrology (Carlton). 2019 Oct;24(10):1056-1063. doi: 10.1111/nep.13530. Epub 2019 Apr 29.

PMID:
30723975
36.

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.

Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V.

Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4.

37.

Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology.

Okpechi IG, Alrukhaimi M, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Johnson DW, Kalantar-Zadeh K, Kazancioglu R, Levin A, Lunney M, Olanrewaju TO, Perkovic V, Perl J, Rashid HU, Rondeau E, Salako BL, Samimi A, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, Bello AK.

Kidney Int Suppl (2011). 2018 Feb;8(2):82-89. doi: 10.1016/j.kisu.2017.10.012. Epub 2018 Jan 19. Review.

38.

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, W Major R, I Schimpf J, Barratt J, Cattran DC, S Gillespie B, Kausz A, W Mercer A, Reich HN, H Rovin B, West M, Nachman PH.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.

39.

Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial.

Jardine MJ, Li N, Ninomiya T, Feng X, Zhang J, Shi J, Zhang Y, Zhang R, Zhang J, Hao J, Perkovic V, Heerspink HL, Wu Y, Yan LL, Neal B.

J Ren Nutr. 2019 Jul;29(4):276-284. doi: 10.1053/j.jrn.2018.10.009. Epub 2018 Dec 24.

40.

Canagliflozin and Stroke in Type 2 Diabetes Mellitus.

Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B.

Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009.

41.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
42.

Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.

Ohkuma T, Jun M, Rodgers A, Cooper ME, Glasziou P, Hamet P, Harrap S, Mancia G, Marre M, Neal B, Perkovic V, Poulter N, Williams B, Zoungas S, Chalmers J, Woodward M; ADVANCE Collaborative Group.

Hypertension. 2019 Jan;73(1):84-91. doi: 10.1161/HYPERTENSIONAHA.118.12060.

43.

New hypoglycemic agents and the kidney: what do the major trials tell us?

Smyth B, Perkovic V.

F1000Res. 2018 Nov 23;7. pii: F1000 Faculty Rev-1844. doi: 10.12688/f1000research.16135.1. eCollection 2018. Review.

44.

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.

Cooper ME, Perkovic V, Groop PH, Hocher B, Hehnke U, Meinicke T, Koitka-Weber A, van der Walt S, von Eynatten M.

J Hypertens. 2019 Jun;37(6):1294-1300. doi: 10.1097/HJH.0000000000002032.

45.

Reducing cardiovascular risk in people with diabetes and kidney disease.

Neuen BL, Perkovic V.

Med J Aust. 2018 Nov 19;209(10):438-439. No abstract available.

PMID:
30428818
46.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

47.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6.

PMID:
30413396
48.

ACCORDION: Ensuring That We Hear the Music Clearly.

Wong MG, Heerspink HJL, Perkovic V.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1621-1623. doi: 10.2215/CJN.11370918. Epub 2018 Oct 25. No abstract available.

49.

Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop.

Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, Tugwell P, Pecoits-Filho R, Crowe S, Harris T, Van Biesen W, Winkelmayer WC, Levin A, Thompson A, Perkovic V, Ju A, Gutman T, Bernier-Jean A, Viecelli AK, O'Lone E, Shen J, Josephson MA, Cho Y, Johnson DW, Sautenet B, Tonelli M, Craig JC; SONG Implementation Workshop Investigators.

Kidney Int. 2018 Dec;94(6):1053-1068. doi: 10.1016/j.kint.2018.08.018. Epub 2018 Oct 22.

50.

Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist".

Matthews DR, Perkovic V, Mahaffey KW.

Circulation. 2018 Aug 7;138(6):660-661. doi: 10.1161/CIRCULATIONAHA.118.035717. No abstract available.

PMID:
30354619

Supplemental Content

Loading ...
Support Center